BDBM233194 Methylprednisolone acetate
Medrol CHEBI:6888 BDBM50103616 Methylprednisolone U-67590A
Alpha-Tocopheryl Succinate (+)-ALPHA-TOCOPHERYL SUCCINATE BDBM50458511
BDBM50044985 ryanodine-hemi-succinate
2-[(ammonioacetyl)amino]succinate BDBM50137024
BDBM26121 Succinic acid, 6 butanedioic acid Succinate SUCCINIC ACID Substrate analogue, 11 succinate, 9
BDBM50137010 2-[(2-ammoniopropanoyl)amino]succinate
Formula 405 BDBM50461794 Pregnenolone Pregnenolone Succinate
BDBM50426137 Diethyl 2-(2-Carbamothioylhydrazono)Succinate CHEMBL2316601
CHEBI:31677 BDBM50016931 HYDROCORTISONE HEMISUCCINATE NSC-7576 Hydrocortisone Succinate
CHEMBL455318 BDBM50263471 Bis[N-propylnoraporphin-11-O-yl]succinate
2-[(2-ammonio-4-oxido-4-oxobutanoyl)amino]succinate BDBM50137037
YM-67905 Solifenacin YM-905 BDBM50344284 Solifenacin succinate vesicare CHEMBL1200803
BDBM50029295 3-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-benzylamine ; succinate
CHEMBL130253 BDBM50014738 N-(Adamantyl-sulfonyl)-N-(methoxy succinate) lys-pro-val-trifluromethane
(S)-Dimethyl 2-(2-((S)-2,6-dioxo-3-(3,4,5-trimethoxybenzamido)piperidin-1-yl)acetamido)succinate BDBM50300410 CHEMBL573033
(S)-dimethyl 2-(2-((S)-2,6-dioxo-3-(3,4,5-trimethoxybenzamido)piperidin-1-yl)acetamido)succinate BDBM50210535 CHEMBL430010
1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-furan-2-ylmethyl}-azepan-2-one;succinate BDBM50029269
1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-furan-2-ylmethyl}-azocan-2-one;succinate BDBM50029285
1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-furan-2-ylmethyl}-piperidin-2-one;succinate BDBM50029243
1-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-furan-2-ylmethyl}-azepan-2-one;succinate BDBM50029276
1-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-furan-2-ylmethyl}-azocan-2-one;succinate BDBM50029244
1-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-furan-2-ylmethyl}-piperidin-2-one;succinate BDBM50029288
BDBM50029246 1-[5-(4-Benzofuran-7-yl-piperazin-1-ylmethyl)-thiophen-2-ylmethyl]-piperidin-2-one;succinate
BDBM50029250 {5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-thiophen-2-yl}-piperidin-1-yl-methanone;succinate
BDBM50135801 CHEMBL413512 di[17-cyclopropylmethyl-(10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] succinate
di[17-cyclobutylmethyl-(10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] succinate BDBM50135798 CHEMBL433697
4-(6,8-Dichloro-3-(2-(dipropylamino)-2-oxoethyl)imidazo[1,2-a]pyridin-2-yl)phenyl Methyl Succinate CHEMBL483172 BDBM50274350
5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrole-2-carboxylic acid isopropylamide;succinate BDBM50029252
5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrole-2-carboxylic acid methylamide;succinate BDBM50029264
5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrole-2-carboxylic acid methylamide;succinate BDBM50029248
BDBM50029284 N-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-acetamide;succinate
CHEMBL1076639 BDBM50312669 2-[2-{1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl}acetamido]ethyl podophyllotoxinyl succinate
BDBM50029261 N-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-N-methyl-acetamide;succinate
BDBM50029262 Pentanoic acid {5-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-methyl-amide;succinate
BDBM50029263 N-Isopropyl-N-{5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-acetamide;succinate
BDBM50029271 N-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-N-methyl-acetamide;succinate
BDBM50029272 Cyclohexanecarboxylic acid {5-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-isopropyl-amide;succinate
BDBM50029282 Cyclohexanecarboxylic acid isopropyl-{5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-amide;succinate
BDBM50029293 N-Benzyl-N-{5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-acetamide;succinate
N-Benzyl-N-{5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-benzamide;succinate BDBM50029274
N-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-N-isopropyl-isobutyramide;succinate BDBM50029267
N-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-N-methyl-isobutyramide;succinate BDBM50029277
N-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-N-methyl-methanesulfonamide;succinate BDBM50029287
N-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-N-methyl-methanesulfonamide;succinate BDBM50029289
Pentanoic acid {5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-methyl-amide;succinate BDBM50029247
BDBM50251125 CHEMBL506257 Bis(2-((2-(7-chloro-6-oxo-6H-dibenzo[cd,g]indazol-2-yl)-ethyl)-methyl-amino)-ethyl) succinate
1-(5-{2-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-ethyl}-1-methyl-1H-pyrrol-2-ylmethyl)-piperidin-2-one;succinate BDBM50029278
1-(5-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-1-methyl-1H-pyrrol-2-ylmethyl)-piperidin-2-one;succinate BDBM50029253
BDBM50029254 Butane-1-sulfonic acid {5-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-methyl-amide;succinate
BDBM50029273 Propane-2-sulfonic acid {5-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-methyl-amide;succinate
Butane-1-sulfonic acid {5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-methyl-amide;succinate BDBM50029286
Propane-2-sulfonic acid {5-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-methyl-amide;succinate BDBM50029279
Succinoylcholine Dicholine succinate Succinocholine Succinylbischoline SUCCINYLCHOLINE suxamethonium CHEMBL703 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium) BDBM50061568 Succinyldicholine
CHEMBL345471 BDBM50014918 2-Imidazol-1-ylmethyl-6-methyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester : (succinate)
CHEMBL345586 4-(2-Difluoromethoxy-phenyl)-2-imidazol-1-ylmethyl-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-ethyl ester 3-methyl ester : (succinate) BDBM50014902
abacavir sulfate BDBM50170965 abacavir succinate 17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one CHEMBL656 Oxycodone
1-(5-{2-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-ethyl}-1-methyl-1H-pyrrol-2-yl)-2-piperidin-1-yl-ethane-1,2-dione;succinate BDBM50029245
1-(5-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-1-methyl-1H-pyrrol-2-yl)-2-piperidin-1-yl-ethane-1,2-dione;succinate BDBM50029256
1-Azepan-1-yl-2-(5-{2-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-ethyl}-1-methyl-1H-pyrrol-2-yl)-ethane-1,2-dione;succinate BDBM50029255
3.303211-(5-{2-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-ethyl}-1-methyl-1H-pyrrol-2-yl)-2-morpholin-4-yl-ethane-1,2-dione;succinate BDBM50029258
4-(2-Chloro-3-trifluoromethyl-phenyl)-2-imidazol-1-ylmethyl-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester : (succinate) CHEMBL351385 BDBM50014908
CHEMBL351115 4-(2-Chloro-3-trifluoromethyl-phenyl)-2-imidazol-1-ylmethyl-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-ethyl ester 3-methyl ester : (succinate) BDBM50014915
(2R,3R,5R,10S,11R,12R,13R,17R)-12-acetoxy-2,11-dihydroxy-4,4,10,13-tetramethyl-17-((R)-6-methyl-5-methyleneheptan-2-yl)-2,3,4,5,6,7,10,11,12,13,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl methyl succinate BDBM50250748 CHEMBL449147
BDBM50246739 CHEMBL446073 (4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-(3-carboxypropanoyloxy)-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Oleanolic acid 3-O-succinate
CHEMBL431685 BDBM50250749 (2R,3R,5R,10S,11R,12R,13R,17R)-12-acetoxy-3,11-dihydroxy-4,4,10,13-tetramethyl-17-((R)-6-methyl-5-methyleneheptan-2-yl)-2,3,4,5,6,7,10,11,12,13,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-2-yl methyl succinate
CHEMBL446317 (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxypropanoyloxy)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid BDBM50292431 3-O-Succinyl-betulinic Acid Betulinic acid 3-O-succinate
(4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-(3-carboxy-3-methylbutanoyloxy)-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid 3-O-(3',3'-dimethylsuccinyl)-oleanolic acid Oleanolic acid 3-O-(3',3'-dimethyl)succinate BDBM50194130 CHEMBL211369
BDBM50175570 Solifenacin vesicare 1-Phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl) ester Solifenacin Succinate CHEMBL439867 905, YM (S)-1-Phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl) ester
(4-Chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine; compound with succinic acid (CGP 79787D) BDBM50121981 (4-chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine succinic acid CHEMBL75232 (4-Chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine; compound with succinic acid(PTK87) N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate
LOXAPINE SUCCINATE Loxapine BDBM55216 cid_71399 butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine 8-chloro-6-(4-methylpiperazino)benzo[b][1,4]benzoxazepine;succinic acid butanedioic acid;8-chloranyl-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine SMR000058470 butanedioic acid;8-chloro-6-(4-methyl-1-piperazinyl)benzo[b][1,4]benzoxazepine MLS000069383
- Deecher, DC; Beyer, CE; Johnston, G; Bray, J; Shah, S; Abou-Gharbia, M; Andree, TH Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318: 657-65 (2006)
- Barlaam, B; Bird, TG; Lambert-Van Der Brempt, C; Campbell, D; Foster, SJ; Maciewicz, R New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem 42: 4890-908 (1999)
- Wacher, VJ; Silverman, JA; Wong, S; Tran-Tau, P; Chan, AO; Chai, A; Yu, XQ; O'Mahony, D; Ramtoola, Z Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther 303: 308-13 (2002)
- Xue, CB; He, X; Roderick, J; Corbett, RL; Duan, JJ; Liu, RQ; Covington, MB; Newton, RC; Trzaskos, JM; Magolda, RL; Wexler, RR; Decicco, CP Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification. Bioorg Med Chem Lett 13: 4293-7 (2003)
- Xue, CB; He, X; Roderick, J; Corbett, RL; Duan, JJ; Liu, RQ; Covington, MB; Qian, M; Ribadeneira, MD; Vaddi, K; Christ, DD; Newton, RC; Trzaskos, JM; Magolda, RL; Wexler, RR; Decicco, CP Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett 13: 4299-304 (2003)
- Blomgren, PA; Currie, KS; Kropf, JE; Lee, SH; Lo, JR; Mitchell, SA; Schmitt, AC; Swaminathan, S; Xiong, J; Xu, J; Zhao, Z Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine US Patent US11517570 (2022)
- ChEMBL_2126975 Inhibition of JMJD6 (unknown origin) by Succinate-Glo assay
- ChEMBL_2126976 Inhibition of KDM3B (unknown origin) by Succinate-Glo assay
- ChEMBL_2126977 Inhibition of KDM4D (unknown origin) by Succinate-Glo assay
- ChEMBL_2126979 Inhibition of ALKBH5 (unknown origin) by Succinate-Glo assay
- ChEMBL_2126980 Inhibition of JMJD7 (unknown origin) by Succinate-Glo assay
- ChEMBL_376968 Inhibition of Septoria nodorum succinate dehydrogenase by FMET2 assay
- ChEMBL_376967 Inhibition of Septoria nodorum succinate dehydrogenase and Qi site of mitochondrial respiratory chain complex 3 by FMET2-3 assay
- ChEMBL_1797942 Irreversible inhibition of KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using alpha-KG by succinate-glo demethylase assay
- ChEMBL_1797935 Irreversible inhibition of KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using 10 uM alpha-KG by succinate-glo demethylase assay
- ChEMBL_1797936 Irreversible inhibition of KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using 100 uM alpha-KG by succinate-glo demethylase assay
- ChEMBL_1797937 Irreversible inhibition of KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using 1000 uM alpha-KG by succinate-glo demethylase assay
- ChEMBL_1797941 Irreversible inhibition of KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using alpha-KG measured immediately by succinate-glo demethylase assay
- ChEMBL_2114144 Inhibition of N-terminal His-tagged human JMJD7 (1 to 316 residues) expressed in Escherichia coli BL21 (DE3) luciferase based succinate-gloTM JmjC demethylase/hydroxylase assay
- ChEMBL_1797938 Irreversible inhibition of 0.4 uM KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using 100 uM alpha-KG by succinate-glo demethylase assay
- ChEMBL_1797939 Irreversible inhibition of 0.8 uM KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using 100 uM alpha-KG by succinate-glo demethylase assay
- ChEMBL_1797940 Irreversible inhibition of 1.6 uM KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using 100 uM alpha-KG by succinate-glo demethylase assay
- ChEMBL_852820 Antagonist activity at human GPR91 receptor expressed in CHO-K1 cells co-expressing Galpha and Gqi5 G-protein assessed as inhibition of succinate-induced increase in intracellular calcium level by FLIPR assay
- ChEMBL_852824 Antagonist activity at rat GPR91 receptor expressed in CHO-K1 cells co-expressing Galpha and Gqi5 G-protein assessed as inhibition of succinate-induced increase in intracellular calcium level by FLIPR assay
- ChEMBL_852825 Antagonist activity at human GPR99 receptor expressed in CHO-K1 cells co-expressing Galpha and Gqi5 G-protein assessed as inhibition of succinate-induced increase in intracellular calcium level at by FLIPR assay
- ChEMBL_1472195 Inhibition of porcine heart SQR in SCR complex assessed as reduction in ubiquinol-cytochrome c reductase (complex 3) activity by measuring cytochrome c level using succinate and DCIP substrate at 23 degC by spectrophotometry
- GTPγS binding test CHO cells stably expressing human metabotropic glutamate receptors mGluR2 and mGluR3 were cultured at 37° C. under 5% CO2 using a Dulbecco's modified Eagle medium [1% proline, 1 mM sodium pyruvate, 1 mM succinic acid, 1 mM disodium succinate, 100 units/mL penicillin, 100 μg/mL streptomycin, 400 (mGluR2) or 300 (mGluR3) μg/mL hygromycin B, 2 mM L-glutamine (added just before use)] containing 10% dialyzed fetal bovine serum. The cells in a confluent state were washed with PBS(−), then dissociated using a cell scraper, and centrifuged at 1000 rpm for 5 minutes at 4° C. to recover the cells. The obtained pellet was suspended in a 20 mM HEPES buffer (pH 7.4) (mGluR2) or 20 mM HEPES buffer containing 1 mM EDTA (pH 7.4) (mGluR3), and the suspension was homogenized in a TeflonŽ homogenizer and then centrifuged at 48,000×g for 20 minutes at 4° C. to obtain a pellet again. The obtained pellet was subjected to two additional cycles of washing and centrifugation and then homogenized with the buffer described above to obtain a crude membrane fraction. The crude membrane fraction was diluted with a buffer for a binding test (final concentration: 20 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 10 μM GDP, 10 ng/mL saponin, 0.1% BSA) (mGluR2) or (final concentration: 20 mM HEPES, 1 mM EDTA, 100 mM NaCl, 10 mM MgCl2, 10 μM GDP, 10 μg/mL saponin, 0.1% BSA) (mGluR3). To the crude membrane fraction containing 10 μg of membrane proteins/assay, Compounds (II)-1 to (II)-15 were each added, and the mixture was incubated at 30° C. for 20 minutes. Then, glutamate (final concentration: 20 (mGluR2) or 1 (mGluR3) μM) and [35S]GTPγS (final concentration: 0.15 nM) were added thereto, and the mixture was incubated at 30° C. for 1 hour. The solution thus incubated was filtered by suction onto Whatman GF/C filter, and the filter was washed with 1000 μL of an ice-cooled 20 mM HEPES buffer (pH 7.4) (mGluR2) or 20 mM HEPES buffer containing 1 mM EDTA (pH 7.4) (mGluR3). A scintillation cocktail was added to the obtained filter, and the membrane binding radioactivity was measured using a liquid scintillation counter. The residual radioactivity in the absence of glutamate was defined as nonspecific binding, and the difference from the residual radioactivity in the presence of glutamate was defined as specific binding.